Everolimus, LBH, and SGN35 available on clinical trials for relapsed Hodgkin Disease at Mayo Clinic
MayoLymphoma
@MayoLymphoma
Thomas Witzig, MD Professor of Medicine at Mayo Clinic. Co-PI Iowa/Mayo Lymphoma SPORE; Co-Chair of the NCTN Lymphoma Clinical Trials Network
7 Following 70 Followers 4 Posts
Latest posts 4
Mayo reports 33% overall response rate to single-agent everolimus for relapsed lymphoma at European Haematology Meeting in Berlin June 7
Dr Micallef reports at ASCO Sat May 30, favorable results of adding a second antibody, epratuzumab, to RCHOP for large cell lymphoma.
Mayo and NW MDs report radioactive Zevalin can be safely combined with chemotherapy and transplant for lymphoma J Clin Oncol 2009; 27:1653